双瓣膜病变伴冠脉高险:江西省心血管病医院洪浪院长带领团队顺利完成1例一站式PBMV+TAVR冠脉高风险手术

2021-07-08 “Clinic門诊新视野”公众号 “Clinic門诊新视野”公众号

2021年6月29日,江西省心血管病医院洪浪院长带领团队完成1例一站式PBMV+TAVR冠脉高风险手术,在医院多学科协同下,手术取得圆满成功,患者苏醒后即刻拔管。术后第一天即下床并转回普通病房。

2021年6月29日,江西省心血管病医院洪浪院长带领团队完成1例一站式PBMV+TAVR冠脉高风险手术,在医院多学科协同下,手术取得圆满成功,患者苏醒后即刻拔管。术后第一天即下床并转回普通病房。

病况概述&术前评估

患者为70岁男性,主诉于1月前开始出现反复胸闷、气逼,常在活动或劳累时发生,每次持续数分钟至半小时不等,休息后可缓解,无头晕、心慌,无心悸、恶心呕吐,无咳嗽、咳痰等不适。为求进一步规范治疗,来我院治疗,门诊拟“风湿性心脏病”收治入科。起病以来,精神、食欲、睡眠尚可。大小便正常,体重无明显改变。

术前心超示:风湿性心脏病,主动脉瓣重度狭窄并中度关闭不全(平均跨瓣压差为90 mmHg、流速4.7 m/s、瓣口面积0.58 cm2);二尖瓣轻中度狭窄并中度关闭不全(瓣口面积1.2 cm2)升主动脉扩张;左室舒张末直径41 mm;EF 59%。

主动脉根部CT示:风湿性三叶瓣,瓣叶增厚约4 mm且左右右融合,钙化主要分布在无冠窦瓣叶,升主动脉扩张,双侧髂股动脉内径可;瓣环周长约79.2 mm(平均直径25.2 mm),环上瓣周长约69 mm(平均直径21.9 mm)左室流出道周长88.1 mm(平均直径28 mm),升主周长124 mm(瓣上40 mm)。左冠高度11.4 mm(瓣叶长约15 mm,左冠开口上缘高度在16 mm左右),右冠高度10.3 mm(瓣叶长约15.9 mm,左冠开口上缘高度在16.5 mm左右),窦宽31.9~34.5 mm。

缜密规划 &精准植入

术前,洪院长组织心内科、心外科、超声科、CCU病房、介入室等科室进行术前策略分析,考虑到患者双瓣膜病变,且呈现风湿性瓣叶增厚,右冠开口较低(右冠闭塞风险高)。经过多层面的讨论后,洪浪院长决定先行二尖瓣球囊成型术(PBMV),再处理主动脉瓣病变,如22 mm球扩影响冠脉血流,则预埋支架及延长导管做冠脉保护,24 VitaFlow(27备选)定位释放。

术中操作全流程:

冠脉造影

房间隔穿刺

二尖瓣球囊扩张

经左股动脉猪尾送至主动脉根部并造影(短径方向投射角度)

跨瓣操作

导丝引导下瓣膜输送至病变处

窦部造影确认瓣膜定位

释放后最终造影显示瓣膜位置良好,微量反流

术后即刻超声良好:平均压差:0 mmHg

为患者至专至精·以匠心诠释精益求精

该例病例的整体难点/特点在于:风湿性三叶瓣,重度狭窄,瓣叶增厚约4 mm;右窦瓣叶较长,且右冠开口低,冠脉高风险;PBMV+TAVR 一站式处理二尖瓣、主动脉瓣狭窄。患者的二尖瓣中度狭窄和主动脉瓣重度狭窄问题需要同时得到解决,而其CT评估结果又提示右冠高闭塞风险。所幸,洪浪院长带领的TAVR团队通过紧密配合、充分评估每个重要环节及其应对措施,为手术的成功奠定了良好基础。

术后,患者的平均跨瓣压差由术前的65 mmHg降至0 mmHg,仅少量瓣周漏。整个手术取得了圆满成功,患者苏醒后即刻拔管。术后第一天即下床并转回普通病房。相比传统开放手术,TAVR术式的优势更明显,无需开胸、心脏停跳及体外循环,手术时间短,失血少,麻醉时间短,微创恢复快。洪浪院长将继续与多学科协同作战,打造江西省心血管病医院一流的瓣膜诊疗团队,持续开展主动脉瓣及其二尖瓣等瓣膜介入手术,帮助更多患者恢复健康,享受高质量的晚年生活!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
    2022-02-07 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]
    2022-05-08 bioon3
  8. [GetPortalCommentsPageByObjectIdResponse(id=1951827, encodeId=fa45195182e8f, content=<a href='/topic/show?id=7df11938efe' target=_blank style='color:#2F92EE;'>#一站式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19387, encryptionId=7df11938efe, topicName=一站式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Mon Feb 07 22:38:26 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078491, encodeId=f67320e849164, content=<a href='/topic/show?id=4a691028160a' target=_blank style='color:#2F92EE;'>#高风险手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102816, encryptionId=4a691028160a, topicName=高风险手术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 23 17:38:26 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819904, encodeId=01a61819904cc, content=<a href='/topic/show?id=f503100109df' target=_blank style='color:#2F92EE;'>#顺利完成#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100109, encryptionId=f503100109df, topicName=顺利完成)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Oct 10 21:38:26 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086418, encodeId=38ee2086418dc, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Mar 08 14:38:26 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644898, encodeId=d0c9164489809, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Thu Nov 11 05:38:26 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862165, encodeId=3fa4186216511, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Nov 01 11:38:26 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976083, encodeId=70d519e6083ba, content=<a href='/topic/show?id=030964356db' target=_blank style='color:#2F92EE;'>#江西省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64356, encryptionId=030964356db, topicName=江西省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sun May 08 10:38:26 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583690, encodeId=0bee15836909a, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Jul 09 11:38:26 CST 2021, time=2021-07-09, status=1, ipAttribution=)]

相关资讯

JAMA: 糖尿病患病率在过去20年持续上升,80%的患者血糖、血压和血脂控制不达标

该项研究分析了1999 到 2018 年美国成人糖尿病患病率变化趋势及美国成人糖尿病患者血糖、血压和血脂控制趋势,结果发现美国在过去20年间的糖尿病管理并不理想,得出糖尿病防控任务仍然非常艰巨。

Hypertension:青年时期血清尿酸变化轨迹与中年心血管疾病事件

青年期血清尿酸升高轨迹与中年期CVD事件相关,这种关联可以用暴露期间的血压水平进行解释。

Heart:油炸食品摄入量与心血管疾病风险和全因死亡率的关系

油炸食品摄入量可能会增加心血管疾病的风险,并呈现线性剂量-反应关系。

J INTERN MED:肌肉强化活动与心血管疾病、2型糖尿病、癌症和死亡风险的关系

尽管数据有限,但建议每周​​超过2.5小时的训练要谨慎。需要进一步研究以更好地了解肌肉强化活动的频率、持续时间和强度对不同人群的主要非传染性疾病和死亡率的影响。

JAHA:膳食和零食与全因、心血管疾病和癌症死亡率的关联

早餐后吃水果、以水果为主的午餐、以蔬菜为主的晚餐和晚餐后喝奶制品与心血管疾病、癌症和全因死亡率降低相关,而西式午餐和主餐后吃淀粉类零食会导致更高的心血管疾病和全因死亡率。

午睡超过60分钟,心血管疾病风险增加34%!教你正确午睡姿势

与不午睡的人相比,午睡超过60分钟的人,全因死亡风险增加了30%,心血管疾病风险增加了34%。